Aug 13 (Reuters) - CytomX Therapeutics Inc CTMX.O:
CYTOMX THERAPEUTICS PROVIDES UPDATE ON CX-2051 PHASE 1 STUDY
CYTOMX THERAPEUTICS INC - CTMX-2051-101 STUDY REMAINS ACTIVE WITH CX-2051 DOSING
CYTOMX THERAPEUTICS INC - PHASE 1 DATA UPDATE EXPECTED BY Q1 2026
Source text: ID:nGNX1xKQDH
Further company coverage: CTMX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.